Insurance and Employment After Immunotherapy — What Cover You Can Still Get

Can You Get Insurance After Cancer Immunotherapy?

Usually yes, but not on the terms you had before, and not immediately. A new retail health policy is underwritten individually and your cancer history is treated as a pre-existing disease. Fresh term life cover is harder again: most Indian insurers want several years of documented disease-free follow-up before they will even consider a proposal.

People arrive at this question late. Treatment finished, the reviews went well, and then a bank asks for life cover against a home loan, or a new employer’s HR form asks about medical history, or a parent abroad tries to buy a policy for someone who has already been treated. Nobody mentioned any of this during treatment, and the guidance that exists online is mostly written to sell a policy rather than to explain one.

The first thing worth separating is underwriting from prognosis. An insurer’s decision is arithmetic about a very large group of applicants who share one line on a form. It is not a statement about how you are doing, it is not a medical opinion, and it should never be read as one. Your oncologist assesses you; an underwriter assesses a category. A decline or a loading tells you what an insurance company decided about risk pricing, and nothing else.

What each kind of cover usually looks like after treatment

Sources: the regulatory limits quoted on this page come from the IRDAI (Insurance Products) Regulations, 2024 and the IRDAI Master Circular on Health Insurance Business, 2024. The rest describes common market practice, which differs between insurers and changes without notice. Treat every line as something to verify against the current policy wording, not as a promise. Any premium or cost figure you are quoted elsewhere is indicative only, as of August 2026.

What Must You Disclose to an Insurer?

Everything the proposal form asks, in writing, unedited. The diagnosis and its date. The treatment, including the immunotherapy drug name and your last dose date. Any immune-related side effect, even a settled one. Every medicine you still take. Your current follow-up. Non-disclosure is the commonest reason a survivor’s claim later fails.

There is a temptation here that deserves to be named rather than lectured about. A cancer history on a form usually means a higher premium or a refusal, and it is human to hope that something treated three years ago and now quiet does not really count. It does. An insurer that discovers an undisclosed history at claim stage is not weighing whether it mattered clinically — it is asking whether the contract was entered into on accurate information.

• The diagnosis, in full. Site, the stage as recorded in your reports, and the date. Copy it from the documents rather than from memory.
• The treatment, by name. That immunotherapy was given, which drug, how many cycles, and the date of the last dose. “Cancer treatment” as a phrase is not a disclosure.
• Immune-related effects, including resolved ones. Thyroid, pituitary, adrenal, lung, bowel, liver or joint problems belong on the form even if they were treated and settled. Our page on long-term side effects of immunotherapy sets out which ones tend to persist.
• Medicines you are still on. Thyroid hormone, steroid replacement or insulin are disclosures of an ongoing endocrine condition, not just tablets. Living with lifelong hormone replacement explains what that involves day to day.
• Your current follow-up. Scan and blood-test intervals and when you were last reviewed. Describing it as clinician-directed surveillance is both accurate and exactly what an underwriter needs to see.

Two legal protections exist, and both reward disclosure rather than substituting for it. For life insurance, Section 45 of the Insurance Act, 1938 provides that a policy cannot be called into question on any ground after three years from the date of the policy, its revival or a rider, whichever is later. For health insurance, the IRDAI moratorium means that once sixty continuous months of coverage are complete, a claim cannot be contested for non-disclosure or misrepresentation — only for established fraud, and for exclusions already written into the contract. Neither protection helps inside those windows, and neither rescues a proposal form that was untrue when it was signed.

Read the completed proposal before you sign it, even when an agent has filled it in for you; you are answerable for what is on it. Ask for a copy of the submitted form and keep it with your treatment records. If an effect from treatment has not gone away, our page on chronic immune effects that do not go away gives you the vocabulary to describe it accurately on a form.

What Waiting Periods Apply After Immunotherapy?

Three clocks usually run at once on a new health policy. A short initial waiting period for illness. A pre-existing-disease waiting period covering your cancer history, capped at 36 months for retail policies under the IRDAI (Insurance Products) Regulations, 2024. And specific waits attached to named illnesses or procedures. A permanent exclusion is not a waiting period and never expires.

This is the one part of the subject where the rules are written down and the same for everybody, which makes it worth knowing precisely. Most confusion at claim stage comes from mixing up a waiting period, which ends, with an exclusion, which does not.

The practical consequence is that continuity is an asset. Waiting periods you have already served travel with you when you port a policy to another insurer at renewal, and credit for continuous coverage also travels when you migrate from a group policy to an individual or family floater policy with the same insurer. Buying a brand-new policy somewhere else instead of porting throws that credit away and starts every clock again at zero. A lapse does the same thing, which is why a missed premium is far more expensive for a survivor than the premium itself.

Nothing here is a prediction about your health, and nothing here is legal or financial advice. Policy wordings differ, regulations are amended, and the only version that governs your claim is the one printed in your own contract on the day you make it.

Do You Have to Tell Your Employer You Had Immunotherapy?

No Indian law obliges you to name your diagnosis to an employer. What you normally need to share is functional rather than clinical: that you need leave, that you have hospital appointments on particular dates, and any adjustment that helps you keep working. Medical certificates go to HR or the company medical officer, not to your manager.

Most people reading this never stopped working. They took leave around infusion days, said as little as possible, and got through it. What surprises them is that the workplace question does not close when treatment does. A fatigue that has not lifted, joints that are stiff until mid-morning, or a steroid dose that has to be increased during any illness are all live issues at work long after the last cycle — and by then the goodwill that surrounded the diagnosis has quietly moved on.

Disclosure at work is best treated as a trade rather than a duty. Saying more can unlock leave, statutory benefits and formal adjustments. Saying less protects your privacy and your standing. Neither choice is braver than the other. Decide what you actually want out of the conversation before you have it.

• Ask for what you need, not for sympathy. “I need a fixed day off every three weeks for a hospital review” is a request a manager can act on. A diagnosis is not.
• Route the paperwork properly. Certificates and fitness-to-work letters belong with HR or the company medical officer under your organisation’s leave policy. Keep copies of everything you hand over.
• If you are ESIC-covered, ask about Extended Sickness Benefit. ESIC lists malignant diseases among the long-term illnesses that qualify, and it runs longer and pays at a higher rate than ordinary sickness benefit, subject to a continuous-employment requirement. Confirm the current rate, duration and conditions with your local ESIC branch, and see our guide to medical leave rights for cancer patients in India.
• Put adjustments in writing. A later start, fewer night shifts, or no travel in the week of a scan. Written requests get recorded and honoured; corridor conversations get forgotten.
• Treat a lasting effect as a work issue, not a character issue. Persistent fatigue is a medical finding to be investigated, not a performance problem to be apologised for.

If you are still on treatment rather than past it, the practical detail sits in can I work during immunotherapy. If a specific effect has settled in for the long term, chronic immune effects that do not go away covers what ongoing management looks like — and what is worth raising at your next review rather than absorbing quietly.

What Happens to Your Cover If You Change or Leave Your Job?

Group cover ends with the employment that provides it. That matters far more for a survivor than for a colleague, because a group policy is issued without individual underwriting and is often the only health cover a survivor still holds. Leaving before a replacement is actually issued is the most expensive mistake in this whole subject.

The sequence people get wrong is simple. They accept a new role, resign, serve notice, and only then discover that the new employer’s cover starts after a probation period, or that the individual policy they applied for has come back declined. There is no way to buy back the years of continuous coverage that lapsed in between.

• Do not resign until the replacement is issued. An offer letter is not a policy. Cover begins when a policy is issued, not when a job is accepted.
• Ask about migration before your last working day. IRDAI rules allow migration from a group policy to an individual or family floater policy with the same insurer, carrying credit for the continuous coverage already served. Ask HR and the insurer in writing while you are still on the payroll.
• Port rather than restart. Porting an individual policy to another insurer at renewal carries your served waiting periods across. Buying a fresh policy elsewhere sets them all back to zero.
• Hold a personal policy alongside the group one if you possibly can. Ideally bought before any diagnosis. If you already have one, never let it lapse over a missed premium.
• Read the new employer’s wording, not the brochure. Most group policies cover pre-existing conditions from day one with no medical test, but sub-limits, room-rent caps and named-condition waits vary widely.

If a relative abroad is funding the treatment. An overseas policy will generally not pay for treatment received in India, and a foreign insurer will treat the same cancer history as pre-existing on any new proposal there too. Where an NRI family member wants to arrange Indian cover for a parent, the underwriting looks at the parent’s health and age, never at the payer’s. Premiums paid for a resident parent may attract a deduction under Indian income-tax law, but the governing statute and the limits have recently changed — confirm the current position with a tax adviser rather than with a policy brochure. For what immunotherapy itself does and does not attract from an insurer, see health insurance cover for immunotherapy in India.

Where Survivorship Questions Usually Go Next

Insurance and employment are the administrative face of a clinical question: what, if anything, is still going on. The pages below cover the medical side of that — which effects tend to persist, what long-term management looks like, and what daily life is like when a gland has been permanently affected. If you want the overall picture of the treatment first, start with immunotherapy at CION Cancer Clinics.

Survivorship Is a Clinical Appointment, Not Just Paperwork

A follow-up review sets what is monitored and how often — and gives you the documented history every insurer and employer eventually asks for.